
PETALING JAYA: Duopharma Biotech Bhd’s net profit for the third quarter ended Sept 30, 2026 (Q3’26) rose 23.9% to RM27.98 million from RM22.57 million a year earlier, supported by improved product mix, lower input costs and operational efficiencies.
Revenue, however, declined 5.6% to RM210.05 million from RM222.49 million previously, mainly due to lower public sector insulin sales following the normalisation of demand after exceptional sales in the first half of 2025, according to a filing with Bursa Malaysia today.
The pharmaceutical group said stronger gross profit margins, improved manufacturing efficiencies and lower imported active pharmaceutical ingredient costs, amid a strengthening ringgit, supported its earnings growth.
For the nine months ended Sept 30, 2026, net profit increased 29.5% to RM88.56 million from RM68.42 million in the corresponding period last year, despite revenue easing 2.1% to RM692.29 million from RM707.01 million.
The group attributed the improved cumulative performance to a more favourable product mix, lower input costs, enhanced manufacturing and operational efficiencies, as well as lower stock write-offs and impairment losses. Lower net finance costs also contributed to the stronger earnings.
It said underlying business growth remained positive, supported by sustained demand from export and private market segments, alongside stronger contributions from its Ethical Specialty and Consumer Healthcare businesses.
For the cumulative nine months, net profit increased 29.5% to RM88.56 million from RM68.42 million a year earlier, already exceeding the group’s full-year FY25 net profit of RM87.46 million.
Looking ahead, Duopharma remains focused on expanding its product portfolio, strengthening manufacturing capabilities and improving operational efficiencies.
The group said its outlook is supported by the government’s continued commitment to strengthening the healthcare sector, including a 2.52% increase in the Health Ministry’s allocation to RM47.7 billion under Budget 2027.
It also highlighted its supply contracts with the Health Ministry, including three insulin contracts worth a combined RM225.85 million, providing revenue visibility over the respective contract periods.
Separately, the group has secured extensions for the supply of 97 pharmaceutical and non-pharmaceutical products under the Approved Products Purchase List for a further six months from Jan 1 to June 30, 2027.
Duopharma also recently signed a five-year exclusive agreement with Taiwan-based Enimmune Corporation for the distribution and sale of vaccines in Malaysia, Singapore and Brunei, beginning with the EnVAX-A71 vaccine for hand, foot and mouth disease, subject to the requisite regulatory approvals.
The group remains cautiously optimistic about delivering a satisfactory performance for the financial year ending Dec 31, 2026.



